Search Results

GSK 3 Inhibitor IX 25 mg  | 99.90%

TargetMol

GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.

More Information Supplier Page

GSK 3 Inhibitor IX 2 mg  | 99.90%

TargetMol

GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.

More Information Supplier Page

Nateglinide 200 mg  | 99.78%

TargetMol

Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Nateglinide has been linked to rare instances of clinically apparent acute liver injury.

More Information Supplier Page

DL-O-Tyrosine 100 mg  | 98.00%

TargetMol

DL-o-Tyrosine is a metabolite of Phenylalanine and is a precursor in the formation of catecholamines. It is used as biomarkers of protein oxidative damage in β-thalassemia.

More Information Supplier Page

DL-O-Tyrosine 200 mg  | 98.00%

TargetMol

DL-o-Tyrosine is a metabolite of Phenylalanine and is a precursor in the formation of catecholamines. It is used as biomarkers of protein oxidative damage in β-thalassemia.

More Information Supplier Page

2′-Deoxyuridine 200 mg  | 99.88%

TargetMol

2′-Deoxyuridine. An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies.

More Information Supplier Page

SCR7 pyrazine 2 mg  | 99.83%

TargetMol

Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).

More Information Supplier Page

SCR7 pyrazine 100 mg  | 99.83%

TargetMol

Enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency in vitro up to 19-fold. Inhibits nonhomologous end-joining (NHEJ).

More Information Supplier Page